biopharma,

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…

4 days ago

Global Biopharma Solutions Leader Selects Kneat to Drive Digital Validation Excellence

LIMERICK, Ireland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), the global leader in digital validation…

1 week ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical…

4 weeks ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025 16:15 ET  | Source: Zenas BioPharma WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.…

4 weeks ago

Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma

 Registrations OPEN India's first of-its-kind, 6th Annual Summit on Biopharmaceutical Product Development in conjunction with the 3rd edition of the International Conference…

4 weeks ago

COSCIENS Biopharma Inc. Announces Leadership Change

TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a…

2 months ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

November 11, 2025 07:05 ET  | Source: Zenas BioPharma WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.…

2 months ago

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST November 02, 2025 19:00 ET  |…

2 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it…

3 months ago

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

August 26, 2025 08:00 ET  | Source: Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE)…

5 months ago